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REVIEW
Quality indicators for the acute 
and long-term management of anaphylaxis: a 
systematic review
Sangeeta Dhami1 , Aadam Sheikh2, Antonella Muraro3, Graham Roberts4,5, Susanne Halken6, 
Monserat Fernandez Rivas7, Margitta Worm8 and Aziz Sheikh9*
Abstract 
Background: The quality of acute and long-term anaphylaxis management is variable and this contributes to the 
poor outcomes experienced by many patients. Clinical practice guidelines have the potential to improve outcomes, 
but implementing guideline recommendations in routine practice is challenging. Quality indicators have the poten-
tial to support guideline implementation efforts.
Objective: To identify quality indicators to support the acute and long-term management of anaphylaxis.
Methods: We conducted a systematic review of the literature that involved searching Medline, EMBASE and CINAHL data-
bases for peer-reviewed published literature for the period 1 January 2005–31 December 2015. Additionally we searched 
Google for grey and unpublished literature. The identified indicators were descriptively summarized against the most recent 
international anaphylaxis guidelines (i.e. those produced by the European Academy of Allergy and Clinical Immunology) 
and critically evaluated using the Agency for Healthcare Research and Quality’s criteria for indicator development.
Results: Our searches revealed 830 publications, from which we identified five sources for 54 indicators addressing 
both acute (n = 27) and long-term (n = 27) management of anaphylaxis. The majority of indicators were developed 
through expert consensus with relatively few of these having been formally piloted or tested to demonstrate that 
they could discriminate between variations in practice and/or that they were sensitive to change.
Conclusions: There is a need for a comprehensive set of quality indicators for anaphylaxis management. We have 
however identified some indicators for the acute and long-term management of anaphylaxis that could with rela-
tively little additional work support efforts to translate guideline recommendations into clinical care.
Keywords: Allergy, Anaphylaxis, Guidelines, Implementation research, Indicators, Outcomes, Quality of care, 
Standards
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publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Anaphylaxis is a “severe, life-threatening general-
ized or systemic hypersensitivity reaction” [1, 2] that 
is responsible for considerable morbidity and, in some 
cases, mortality. The quality of emergency and ongo-
ing care for patients experiencing and/or with a history 
of anaphylaxis is variable and this contributes to the 
poor outcomes (e.g. high risk of recurrent episodes of 
anaphylaxis) seen [3]. In an attempt to standardize care, 
and thereby improve outcomes, a number of govern-
ments and professional bodies have developed clinical 
practice guidelines [4–7]. These aim to provide front-line 
clinicians with simple, concise, evidence-based recom-
mendations for clinical care. Whilst undoubtedly a wel-
come development, there is a growing body of evidence 
demonstrating that guidelines often prove challenging 
to implement in routine clinical care [8]. To support 
this implementation process, attention is increasingly 
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focusing on the need to develop tools that can help clini-
cians implement key recommendations and monitor pro-
gress with implementation efforts [9].
Quality standards and indicators are potentially impor-
tant tools designed to help clinicians and healthcare 
organisations assess the quality of care being provided 
against agreed evidence-based recommendations [9]. 
These are now being used across a number of disease 
and clinical areas, but we are unaware of these currently 
being routinely used at scale in relation to anaphylaxis.
We are developing evidence-based tools to support 
translation of key anaphylaxis recommendations into 
clinical practice and in order to inform this process we 
undertook a systematic review to identify existing quality 
indicators for anaphylaxis and identify gaps where there 
is a need for further development.
Methods
Overview of methods, registration and reporting
We conducted a systematic review of the literature that 
involved searching for published and unpublished lit-
erature. It is registered in the PROSPERO database with 
registration number CRD42016035381. We reported 
findings using the principles advocated in the PRISMA 
guidelines [10] (Additional file 1).
Search strategy
 We developed a highly sensitive search strategy to iden-
tify papers on standards and/or quality indicators for 
anaphylaxis. This involved searching Medline, EMBASE 
and CINAHL databases for peer-reviewed published lit-
erature, and the Google database for searching grey lit-
erature published during the period 1 January 2005–31 
December 2015. No language restrictions were employed. 
Our search terms are detailed in the Appendix.
Inclusion criteria
We were interested in publications reporting on indica-
tors for measuring the quality of acute and long-term 
care of anaphylaxis in patients of any age. We did not 
specify any criteria on how these were developed and 
there was therefore no study filter employed in selecting 
papers.
Selection of indicators
Two reviewers independently selected manuscripts 
against the pre-specified inclusion criteria. Disagree-
ments were resolved through discussion with arbitration 
by a third reviewer, where necessary.
Data extraction
Two reviewers independently extracted indicator data 
onto a customized data extraction sheet. Disagreements 
were resolved through discussion; a third reviewer 
arbitrated in instances where agreement could not be 
reached. Where available, we also extracted data on how 
these indicators were developed, whether they had been 
tested and if they had been used in experimental contexts 
to demonstrate that they could capture improvements in 
the quality of care.
Quality assessment of indicators
The quality of these indicators was then assessed against 
the criteria detailed using the four stage quality indica-
tor process recommended by the Agency for Healthcare 
Research and Quality (AHRQ), namely:
1. Development: Identifying candidate indicators 
through a literature review and/or discussion with 
experts;
2. Implementation: Testing of candidate indicators, 
introducing them into software etc.;
3. Maintenance: Indicators need to be regularly checked 
and, if necessary, updated to keep abreast of latest 
developments; and
4. Retirement processes: Indicators need to be assessed 
at periodic intervals for relevance and in order to 
assess if they need to be discontinued [11].
We contacted the authors of these development tools 
for further clarification, if necessary.
Data synthesis
We then mapped available indicators against the vari-
ous recommendations in the most recent international 
anaphylaxis guidelines, namely those produced by the 
European Academy of Allergy and Clinical Immunology 
(EAACI) [12], identifying areas of overlap and gaps, and 
making an overall assessment of whether any particular 
indicator was considered appropriate for use in routine 
clinical practice. Available indicators were traffic-light 
color coded with green indicating that the indicators 
were suitable/nearly suitable for routine use as they had 
undergone the AHRQ process, amber indicating the 
need for some additional work, and red indicating the 
need for a substantial amount of additional underpinning 
work as most of the stages suggested by AHRQ had not 
been followed.
Results
Characteristics of included studies
Our searches identified 830 studies, of which five satis-
fied our inclusion criteria (see Fig.  1) [12–16]. The five 
sources of indicators are detailed in Table 1. In total, 54 
individual indicators were identified: 27 for the acute 
management of anaphylaxis and the remaining 27 for 
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longer-term management. Indicators for the acute and 
longer-term management of anaphylaxis were identi-
fied by four of the five sources [12, 14–16]. Two sources 
of indicators only focused on children and young people 
[16, 17], and one focused solely on children attending 
Emergency Departments (ED) for the acute management 
of anaphylaxis [17].
Geographically, three sets of indicators were developed 
in the United Kingdom (UK) [14–16], the fourth was 
developed in Canada [17] and the fifth was pan-European 
in origin [12].
Assessment of indicators against AHRQ criteria
Table 2 summarizes our assessment of the quality of the 
indicators against each of the four criteria stipulated by 
AHRQ.
1. Measure development
 The EAACI indicators [12] were derived from clini-
cal guidelines in relation to key recommendations. The 
Levy indicators [14] were developed through expert 
consensus. The National Institute of Health and Clini-
cal Excellence (NICE) indicators were derived from 
relevant guideline recommendations [15]. The Royal 
College of Paediatrics and Child Health (RCPCH) indi-
cators were derived from a care pathway for children 
with suspected anaphylaxis [16]. The Stang indica-
tors [17] were the only ones that had been developed 
through the stages suggested by AHRQ, namely formal 
processes to identify and assess indicators; further-
more, these were developed using National Quality 
Framework (NQF) measure evaluation criteria [19].
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Fig. 1 PRISMA flow diagram for anaphylaxis indicators
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2. Implementation
 The EAACI indicators [12] did not have any for-
mal implementation assessment. The Levy indica-
tors [14] are freely available for use from http://www.
guideline-audit.com/adrenaline/audit_specification.
php and had been successfully implemented in a num-
ber of UK general practices with the opportunity for 
benchmarking quality of care. NICE [15] had a generic 
implementation team and created a range of imple-
mentation tools, but it was unclear if the ability to 
implement these indicators in practice had been for-
mally assessed. The RCPCH [16] give no mention of 
an implementation strategy. The Stang indicators were 
operationalized and tested in an ED setting [17].
3. Maintenance
 None of the indicators had plans for formal mainte-
nance checks.
4. Retirement
 There were no plans for retirement of indicators, 
although EAACI [12], NICE [15] and the RCPCH [16] 
stated that they had established processes for the peri-
odic review of their clinical guidelines/pathways.
Mapping of indicators against guideline recommendations
The EAACI Guidelines [12] made 16 recommendations 
on the acute management of anaphylaxis and indicators 
were developed by EAACI for all of these recommenda-
tions (Table  3). Six of these recommendations also had 
indicators identified from the other sources.
For the longer-term management of anaphylaxis, 
EAACI made eight recommendations and indicators 
were developed by EAACI for all of these (Table 4). Addi-
tional indicators from other sources were identified for 
five of these recommendations.
Tables  3 and 4 have been colour coded according to 
their compliance with the AHRQ criteria to show which 
indicators are fit-for-purpose. Green identifies indicators 
that have been developed according to AHRQ princi-
ples and are ready to implement, red shows the indica-
tors that need more developmental work before they can 
be implemented and amber falls between the two. These 
tables show that the Stang et  al. [17] (coded green) and 
Levy [14] (coded amber) indicators could with relatively 
modest effort be rendered fit-for-purpose; gaps still how-
ever remained in relation to both acute and long-term 
management (coded red) where considerable develop-
ment work is still required.
Discussion
Statement of principal findings
This study has demonstrated that there are now can-
didate quality indicators covering many aspects of the 
acute and long-term management of anaphylaxis. Only 
a few of these have however undergone the four stages 
of development recommended by AHRQ, namely imple-
mentation and maintenance and none of them have con-
sidered decisions on the maintenance or retirement of 
quality indicators [11]. Further work is therefore needed 
before any of these can be recommended for routine use 
in clinical practice [17]. That said, the indicators devel-
oped by Stang et  al. [16] for acute management of ana-
phylaxis and those developed by Levy [14] for long-term 
management could be rendered fit-for-purpose with 
relatively modest additional effort. EAACI should there-
fore consider undertaking this work and adopting these 
indicators. Other areas in relation to both acute and 
long-term management require much more development 
work and evaluation.
Strengths and limitations
The key strengths of this work are that we used sys-
tematic review methods to identify relevant literature, 
Table 1 Source of indicators for the acute and long-term management of anaphylaxis
Author, year, country Title Indicators for the 
acute management 
of anaphylaxis
Indicators for the 
long-term manage-
ment of anaphylaxis
No of indicators
European Academy of Allergy and 
Clinical Immunology (EAACI), 2014, 
Europe
Anaphylaxis: guidelines from the European 
Academy of Allergy and Clinical Immu-
nology
Yes Yes 24
Levy M, 2008, UK Audit of self-administered injectable 
adrenaline prescription in primary care
Yes Yes 6
National Institute for Health and Clini-
cal Excellence (NICE), 2011, UK
Anaphylaxis clinical audit tool implement-
ing NICE guidelines
Yes Yes 8
Royal College of Paediatrics and Child 
Health (RCPCH), 2011, UK
RCPCH Allergy Care Pathways Project Audit 
criteria
Yes Yes 9
Stang AS, et al., 2013, Canada Quality indicators for high acuity pediatric 
conditions
Yes No 7
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Table 3 Indicators for the acute management of anaphylaxis mapped to EAACI recommendations with assessment of indi-
cator quality
Recommendaon Indicator Source
Adrenaline is potenally life-
saving and must therefore 
promptly be administered as 
the first-line treatment for the 
emergency management of 
anaphylaxis
% of children treated with an intramuscular 
adrenaline injecon for an acute anaphylaxis 
reacon
% of paents with anaphylaxis who received 
epinephrine in ED
100% of paents prescribed Adrenaline Auto-
injectors should be for the correct dose
% of paents at risk of anaphylaxis who have an 
unexpired adrenaline auto-injector
% of paents experiencing anaphylaxis who are 
promptly treated with adrenaline
The me of onset of the reacon should be 
recorded
Stang et al
Stang et al
Levy
EAACI
EAACI
NICE
Earlier administraon of 
adrenaline should be 
considered on an individual 
basis when an allergic reacon 
is likely to develop into 
anaphylaxis
% of paents experiencing anaphylaxis who are 
promptly treated with adrenaline
EAACI 
Adrenaline should be % of paents treated with epinephrine in ED Stang et al
administered by intramuscular 
injecon into the mid outer 
thigh
treated by the appropriate route
% of children treated with an intramuscular 
adrenaline injecon for an acute anaphylaxis 
reacon
% of paents who give the auto-injector into the 
mid-outer thigh
Percentage of children treated with an 
intramuscular adrenaline injecon for an acute 
anaphylaxis reacon
Stang et al
NICE
RCPCH
In paents requiring repeat 
doses of adrenaline, these 
should be administered at 
least 5 minutes apart
% of paents treated with >1 dose adrenaline, 
ming and who administered (parents, 
paramedics, self)
EAACI 
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Table 3 continued
With inadequate response to 
2 or more doses of 
intramuscular adrenaline, 
adrenaline may be 
administered as an infusion by 
appropriately experienced 
intensive care, emergency 
department and crical care 
physicians, with appropriate 
cardiac monitoring
% of paents requiring intensive care support 
with anaphylaxis
Outcome if require ≥ 2 doses intramuscular 
adrenaline
EAACI 
Trigger of the anaphylaxis 
episode should be removed
Time taken for removal of trigger among paents 
with anaphylaxis from medicaon or blood 
products
The circumstances immediately before the onset 
of symptoms should be recorded to help to 
idenfy the possible trigger
EAACI 
NICE
Help should be called Whether and when help is called EAACI  
promptly and simultaneously 
with paent’s assessment
Paents experiencing 
anaphylaxis should be 
posioned supine with 
elevated lower extremies if 
they have circulatory 
instability, sing up if they 
have
respiratory distress and in 
recovery posion if 
unconscious
In paents with previous anaphylaxis, determine 
proporon of paents placed in the correct 
position whilst receiving treatment
EAACI  
High flow oxygen should be 
administered by face mask to 
all paents with anaphylaxis
% of paents with anaphylaxis that were given 
high flow oxygen  in the community (ambulance) 
and in hospital
EAACI  
Intravenous fluids 
(crystalloids) should be 
administered (boluses of 20 
ml/kg) in paents 
experiencing cardiovascular 
instability
% of paents with anaphylaxis who received IV 
fluids (bolus and maintenance)
% of paents with blood pressure measurement 
as part of inial observaons
EAACI 
EAACI 
Inhaled short-acng beta-2 
agonists should addionally 
be given to relieve symptoms 
of bronchoconstricon
% of paents with  lower respiratory symptoms in 
the context of anaphylaxis given adrenaline
% of paents with  lower respiratory symptoms in 
the context of anaphylaxis inhaled beta-2-
agonists but not adrenaline
EAACI  
EAACI 
Recommendaon Indicator Source
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formally considered the appropriateness of the methods 
to develop and deploy these indicators using the four 
stage process recommended by the AHRQ [11] and then 
systematically mapped these against the recent EAACI 
anaphylaxis guidelines [5].
Table 3 continued
Oral H1- (& H2)-
anhistamines may relieve 
cutaneous symptoms of 
anaphylaxis
% of paents with anaphylaxis who self-
administered anhistamines prior to adrenaline
EAACI 
Systemic glucocorcosteroids 
may be used as they may 
reduce the risk of late phase 
% of paents who received adrenaline treatment 
with and without glucocorcocosteroids
EAACI 
respiratory symptoms. High 
dose nebulized glucocorcoids 
may
be beneficial for upper airway 
obstrucon
Paents who presented with 
respiratory compromise 
should be closely monitored 
for at least 6-8 hours and 
paents who presented with 
circulatory instability require 
close monitoring for 12-24 
hours
% of paents discharged within 6 hours 
compared to > 24 hours and outcome of reacon 
e.g. development of biphasic response, or need 
for repeat dose adrenaline
% of children with an acute episode of 
anaphylaxis transferred to hospital
% of children with an acute episode of 
anaphylaxis who are transferred to hospital are 
observed for a minimum of 4 hours
All children younger than 16 years given 
emergency treatment for suspected anaphylaxis 
should be admied to hospital under the care of 
a paediatric medical team
EAACI 
RCPHCP
RCPHCP
NICE
Before discharge, the risk of 
future reacons should be 
assessed and an adrenaline 
auto-injector should be 
prescribed to those at risk of 
recurrence
% of paents prescribed adrenaline auto-injector 
upon discharge following anaphylaxis
Aer emergency treatment for suspected 
anaphylaxis, people (or, as appropriate, their 
parent and/or carer) should be offered an 
appropriate adrenaline injector as an interim 
measure before the specialist allergy service 
appointment
EAACI 
NICE
Recommendaon Indicator Source
The limitations of this work also need to be considered. 
This includes the possibility that we failed to identify 
relevant literature and indicators, although we tried to 
minimize this risk by not having any restriction of lan-
guages on our searches, searching grey literature and by 
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are in widespread use in hospital practice focusing, for 
example, on re-hospitalization of patients within 30 days 
of discharge, which can be used to penalize hospitals [22, 
23]. By imposing financial penalties for those with the 
highest readmission rates and thus penalizing those with 
poor levels of care, the hope is to improve the quality of 
care delivered [24].
Implications for policy, practice and research
Indicator development, implementation testing, and 
maintenance and retirement considerations should be 
seen as integral to the process of producing guidelines 
as this will maximize the chances of translating guide-
line recommendations into routine clinical practice 
and thereby improve outcomes. Quality indicators can 
improve this translational process through associated 
financial incentives and penalties as noted above, but 
they can also be used in more subtle ways through, for 
Table 3 continued
measures (where possible) 
and instrucons for the use of 
the
adrenaline auto-injector. 
Specialist and food allergy 
specialist diean (in food 
anaphylaxis) follow-up should 
be organized. Contact 
informaon for
paent support groups should 
also be provided
Aer emergency treatment for suspected 
anaphylaxis, people should be offered a referral 
to a specialist allergy service
Before discharge a healthcare professional with 
the appropriate skills and competencies should 
offer people (or, as appropriate, their parent 
and/or carer) the following:
•informaon about anaphylaxis, including the 
signs and symptoms of an anaphylacc reacon
•informaon about the risk of a biphasic reacon
•informaon on what to do if an anaphylacc 
reacon occurs (use the adrenaline injector and 
call emergency services)
•a demonstraon of the correct use of the 
adrenaline injector and when to use it
•advice about how to avoid the suspected trigger 
(if known)
•informaon about the need for referral to a 
specialist allergy service and the referral process
•informaon about paent support groups
NICE
NICE
Recommendaon Indicator Source
Paents should be provided 
with a discharge advice sheet, 
including allergen avoidance 
% of paents with discharge advice sheet and 
training on use of adrenaline auto-injector upon 
discharge following anaphylaxis
EAACI 
contacting a panel of experts. There may also have been 
experiences of using these indicators that have not yet 
found their way into the peer-reviewed or grey litera-
ture. This issue could be further investigated through, for 
example, contacting electronic health record and soft-
ware vendors to see which if any have been computed 
and with what results.
Interpretation in the light of other published literature
Anaphylaxis, in comparison to other disease areas, is 
relatively undeveloped in terms of quality indicators [18]. 
For example, NICE has developed indicators for a num-
ber of disorders—particularly long-term conditions—
that have been used to incentivize improvements in 
care through the UK Quality and Outcomes Framework 
(QOF) [19, 20]. Examples of areas in which these have 
been used include asthma, atrial fibrillation, blood pres-
sure and cancer care [21]. Similarly, in the US indicators 
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example, benchmarking efforts, supporting audit cycles 
and quality improvement initiatives. These comparative 
processes, particularly if they involve financial incentives 
and fines or reputational damage, need to be undertaken 
with care and with appropriate case mix adjustment, if 
appropriate [25].
Key next steps are for a multi-stakeholder group to for-
mally consider these existing candidate indicators, chose 
between existing indicators, propose alternative indi-
cators where considered necessary, develop additional 
indicators to fill the recommendation gaps, and then 
undertake formal field work to support implementation 
efforts. In due course, plans also need to be put into place 
to consider indicator maintenance and retirement related 
issues. The AHRQ framework can prove useful to guide 
this process [11].
Conclusions
Indicators were identified for all of the recommenda-
tions made in the EAACI Anaphylaxis Guidelines, though 
none of these satisfied all four criteria specified by AHRQ. 
There are some indicators, particularly in relation to 
Table 4 Indicators for the longer-term management of anaphylaxis mapped to EAACI recommendations with assessment 
of indicator quality
Recommendaon Indicator Source
An anaphylaxis management 
plan should be used from the 
me of diagnosis
to prevent future reacons, 
and aid recognion and 
treatment of any further 
reacons
100% of paents with a recorded diagnosis of 
anaphylaxis have evidence of receiving a wrien 
self-management plan.
At least 80% of paents with a recorded diagnosis 
of anaphylaxis have been reviewed in the past 
year?
100% of paents or their parents/ 
representaves with a prescripon for self-
administered adrenaline should have been taught 
to use device.
At least 80% of paents or their parents/ 
representaves have demonstrated they can use 
their autoinjector, in the past 12 months
At least 80% of paents with a prescripon for 
self-administered adrenaline have a recorded 
diagnosis of anaphylaxis?
% of paents aended the ED because of a 
further severe allergic reacon and length of ED 
stay
Levy
Levy 
Levy 
Levy 
EAACI 
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Table 4 continued
stay EAACI
% of paents died because of a further severe 
allergic reacon
The acute clinical features should be documented
The circumstances immediately before the onset 
of symptoms should be recorded to help to 
idenfy the possible trigger
Aer emergency treatment for suspected 
anaphylaxis, people should be offered a referral 
to a specialist allergy service
Aer emergency treatment for suspected 
anaphylaxis, people (or, as appropriate, their 
parent and/or carer) should be offered an 
appropriate adrenaline injector as an interim 
measure before the specialist allergy service 
appointment
Percentage of children with an acute episode of 
anaphylaxis who are invesgated with specific 
allergy tests
Percentage of children who carry an adrenaline 
injector who have been weighed for a review of 
their adrenaline dose
Percentage of children (and their families) at risk 
of anaphylaxis educated to use an adrenaline 
injector at every health care visit for their acute
severe allergies
EAACI 
EAACI 
NICE
NICE
NICE
NICE
RCPCH
RCPCH
RCPCH
Recommendaon Indicator Source
% of paents hospitalized because of a further 
severe allergic reacon and length of hospital 
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acute management, which would require relatively little 
effort to render them fit-for-purpose. We also identified 
some indicators, which may prove suitable in relation to 
assessing the quality of long-term anaphylaxis care. Other 
indicators, however, require much more developmental 
work. To progress this work, stakeholders now need to 
consider the findings from this review and then under-
take additional formative work to ensure that there are a 
Table 4 continued
Percentage of children with anaphylaxis where 
the health professionals ensured that schools and 
early years sengs are informed of how to deal 
with an acute event
RCPCH
RCPCH
Subcutaneous venom 
immunotherapy is 
recommended in venom 
allergic paents with a 
previous episode of 
anaphylaxis and adults with 
systemic 
cutaneous reacons
% of paents who have an increased quality of 
life compared to those without treatment
EAACI 
Training in the recognion and 
management of anaphylaxis 
should be offered to all 
paents and caregivers of 
children at risk of anaphylaxis 
ideally from
the me of diagnosis
100% of paents or their parents/ 
representaves with a prescripon for self-
administered adrenaline should have been taught 
to use device.
At least 80% of paents or their parents/ 
representaves have demonstrated they can use 
their autoinjector, in the past 12 months
100% of paents with a recorded diagnosis of 
anaphylaxis have evidence of receiving a wrien 
self-management plan
Adrenaline auto-injector training devices should 
be available in physician offices or hospitals; if no 
me for training immediate referral to allergist
Levy
Levy 
Levy 
EAACI 
Recommendaon Indicator Source
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Table 4 continued
The acute clinical features should be documented
Percentage of children (and their families) at risk 
of anaphylaxis educated to use an adrenaline 
injector at every health care visit for their acute 
severe allergies
Percentage of children with anaphylaxis where 
the health professionals ensured that schools and 
early years sengs are informed of how to deal 
with an acute event
NICE 
RCPCH
RCPCH
Training in the recognion and 
management of anaphylaxis, 
including use of adrenaline 
auto-injectors, should be 
offered to all professionals 
dealing with paents at risk of 
anaphylaxis
% of  EDs with clinical guidelines for the 
treatment of anaphylaxis in children
% of healthcare professionals who are trained in 
the recognion and management of anaphylaxis
Stang et al
EAACI
Training packages should be 
developed with the target 
groups
Number and quality of anaphylaxis training 
packages
EAACI 
Training should cover allergen 
avoidance, symptoms of 
allergic reacons, when and 
how to use an adrenaline 
auto-injector and what other 
measures are needed within 
the context of an anaphylaxis 
management plan
100% of paents or their parents/ 
representaves with a prescripon for self-
administered adrenaline should have been taught 
to use device.
At least 80% of paents or their parents/ 
representaves have demonstrated they can use 
their autoinjector, in the past 12 months
% of paents or caregivers who receive training
Levy
Levy 
EAACI
Recommendaon Indicator Source
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range of suitable indicators that have been both appropri-
ately developed and demonstrated to work in practice to 
achieve the desired outcome, namely helping to assess the 
quality of anaphylaxis care delivered to patients.
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Table 4 continued
Training may involve more 
than one session to allow 
revision, an interacve
scenario-based approach, a 
standardized program with 
manual and educaonal 
material and simulaon tools. 
Content and language should 
be tailored to be understood 
and memorized
At least 80% of paents with a recorded diagnosis 
of anaphylaxis have been reviewed in the past 
year?
100% of paents or their parents/ 
representaves with a prescripon for self-
administered adrenaline should have been taught 
to use device.
% of paents or caregivers who receive training
Levy
Levy 
EAACI
Educaonal intervenons 
should ideally incorporate 
psychological principles
and methods to address 
anxiety so that children and 
families may funcon
well at home, at school/work, 
and socially despite their risk 
of future reacons
and should ideally be part of 
their educaonal training. This 
can be done in a
group format. Some paents, 
with severe anxiety of ongoing 
duraon, may need more in-
depth one to one 
psychological intervenon
Opmizaon of adapve anxiety levels in trained 
paents and caregivers
EAACI 
Recommendaon Indicator Source
Green, amber and red show which indicators have been developed according to AHRQ criteria, green being the closest and red the furthest
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Appendix
Search strategy 1: MEDLINE and EMBASE
 1. anaphylaxis/
 2. anaphyl*.mp.
 3. ((acute or severe or major or serious or life threaten-
ing or fatal*) and (allerg* or hypersensiti*)).mp.
 4. hypersensitivity immediate/
 5. exp food hypersensitivity/
 6. respiratory hypersensitivity/
 7. exp drug hypersensitivity/
 8. ((food or egg? or nut? or peanut? or milk or wheat or 
drug? or respiratory or asthma* or sting* or venom*) 
adj3 (allerg* or hypersensiti*)).tw.
 9. ((allerg* or hypersensiti*) adj5 reaction*).tw.
 10. or/1–9
 11. quality indicators.mp. or exp Quality Indicators, 
Health Care/
 12. quality standard.mp.
 13. “Process Assessment (Health Care)”/or clinical best 
practice.mp.
 14. clinical audit.mp. or exp Clinical Audit/
 15. patient experience.mp.
 16. (quality and outcomes framework).mp.
 17. or/11–16
 18. 10 and 17
Search strategy 2: CINAHL
(anaphylaxis or anaphylaxis management) AND (quality 
indicators or quality standard or clinical audit or patient 
experience).
Search strategy 3: Google Scholar
Free key word search “anaphylaxis management and 
quality indicators 2005–2015.
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